XY Capital Ltd Buys Shares of 36,769 ResMed Inc. $RMD
XY Capital Ltd acquired 36,769 shares of ResMed Inc. (NYSE:RMD) during the second quarter, making it their fourth-largest holding and representing 6.9% of their portfolio, valued at approximately $7.17 million. ResMed recently reported strong quarterly results, exceeding expectations with earnings of $2.95 per share and revenue of $1.46 billion, an 8.6% increase year-over-year. The company also increased its quarterly dividend to $0.66 per share, while analysts maintain a consensus "Hold" rating with a target price of $239.38.
Paralel Advisors LLC Buys Shares of 10,293 ResMed Inc. $RMD
Paralel Advisors LLC has acquired 10,293 shares of ResMed Inc. (NYSE:RMD) stock, valued at approximately $2.0 million, marking a new position for the institutional investor. Other major investors, including Hsbc Holdings PLC and Goldman Sachs Group Inc., also increased their holdings in ResMed. Despite mixed analyst ratings with an average "Hold," ResMed reported strong Q2 earnings, surpassing EPS estimates and increasing revenue by 8.6% year-over-year, alongside a quarterly dividend hike.
SGL Investment Advisors Inc. Purchases New Position in ResMed Inc. $RMD
SGL Investment Advisors Inc. has acquired a new stake in ResMed Inc. (NYSE:RMD), purchasing 10,409 shares valued at approximately $2.29 million. Other institutional investors have also recently adjusted their positions in the company, which saw its stock open at $228.81 and has a market cap of $33.01 billion. ResMed recently reported strong earnings, exceeding analyst estimates, increased its quarterly dividend to $0.66 per share, and has a consensus "Hold" rating from analysts with a price target of $239.38.
Wealthfront Advisers LLC Makes New Investment in ResMed Inc. $RMD
Wealthfront Advisers LLC has acquired 8,748 shares of ResMed Inc. (NYSE:RMD) in the second quarter, a new investment valued at approximately $1.7 million. This move is part of broader institutional investor activity, with several other hedge funds also establishing new positions in ResMed. The article also details recent analyst ratings, financial performance, a dividend increase, and insider stock sales for ResMed.
OVERSEA CHINESE BANKING Corp Ltd Makes New Investment in ResMed Inc. $RMD
OVERSEA CHINESE BANKING Corp Ltd has acquired a new position in ResMed Inc. (NYSE:RMD) during the second quarter, purchasing 24,458 shares valued at approximately $4.766 million. This investment comes as ResMed recently reported strong Q2 earnings, beating analyst estimates, and increased its quarterly dividend to $0.66 per share. Analyst ratings for ResMed are mixed, with an average "Hold" rating and an average price target of $239.38.
10,000 Shares in ResMed Inc. $RMD Bought by OVERSEA CHINESE BANKING Corp Ltd
OVERSEA CHINESE BANKING Corp Ltd recently acquired 10,000 shares of ResMed Inc. (NYSE:RMD), valued at approximately $1.95 million, in the second quarter. Other institutional investors like BlackRock Inc. and State Street Corp also significantly increased their holdings. However, company insiders, including CEO Michael J. Farrell and Director Peter C. Farrell, sold a combined total of 22,973 shares worth over $4.8 million in recent transactions.
13,498 Shares in ResMed Inc. $RMD Purchased by Fairtree Asset Management Pty Ltd
Fairtree Asset Management Pty Ltd has acquired a new stake of 13,498 shares in ResMed Inc. (NYSE:RMD), valued at approximately $2.63 million, making it the 24th largest position in their investment portfolio. Other institutional investors like BlackRock Inc. and State Street Corp also hold significant stakes in ResMed, with institutional ownership accounting for 54.98% of the company's stock. ResMed recently reported strong financial results, including an EPS of $2.95 and revenue of $1.46 billion for the quarter, and increased its quarterly dividend to $0.66 per share.
Danske Bank A S Makes New Investment in ResMed Inc. $RMD
Danske Bank A S has made a new investment in ResMed Inc. (NYSE:RMD), purchasing 88,341 shares valued at approximately $17.2 million in the second quarter. ResMed exceeded its quarterly earnings expectations with an EPS of $2.95 and an 8.6% year-over-year revenue growth. Despite some analyst target reductions, the company maintains a consensus "Hold" rating with a $239.38 price target and recently increased its quarterly dividend.
Bank of New York Mellon Corp Takes $818.03 Million Position in ResMed Inc. $RMD
Bank of New York Mellon Corp has acquired a significant position in ResMed Inc. (NYSE:RMD), purchasing over 4.19 million shares valued at approximately $818.03 million in the second quarter. This move positions Bank of New York Mellon Corp as a major institutional investor, owning about 2.89% of ResMed. The article also details other hedge fund activities, analyst ratings, insider transactions, and ResMed's recent financial performance, including its increased quarterly dividend.
ResMed Stock Bounces Back 4% This Week After Erasing Its Post Earnings Selloff
ResMed (RMD) stock gained 4% this week, recovering from a post-earnings selloff despite cautious fiscal 2027 guidance. The company reported record Q4 fiscal 2026 revenue and EPS but projected slower core revenue growth due to the sale of MatrixCare, a temporary suspension of Astral ventilator sales, and dilution from the Noctrix acquisition. The article suggests that ResMed's core sleep business remains strong and that the stock's current valuation reflects market caution, with potential for reacceleration once headwinds subside.
ResMed (NYSE:RMD) Upgraded to Hold at Rothschild & Co Redburn
Rothschild & Co Redburn upgraded ResMed (NYSE:RMD) to a "Hold" rating, aligning with the broader analyst consensus. Despite recent insider stock sales, ResMed exceeded Q2 earnings expectations with $2.95 EPS and $1.46 billion in revenue. The stock has a current market capitalization of $33.30 billion and a P/E ratio of 22.13.
350,860 Shares in ResMed Inc. $RMD Acquired by Mitsubishi UFJ Asset Management Co. Ltd.
Mitsubishi UFJ Asset Management Co. Ltd. has acquired a new position in ResMed Inc. (NYSE:RMD), purchasing 350,860 shares valued at approximately $68.38 million. This acquisition makes Mitsubishi UFJ Asset Management Co. Ltd. the owner of about 0.24% of ResMed's stock. The article also details other institutional investor activity, analyst ratings, and recent insider transactions for ResMed.
ResMed Inc. stock rises Wednesday, outperforms market
ResMed Inc. (RMD) shares rose 4.85% on Wednesday, closing at $230.65, outperforming the broader market. This gain snapped a three-day losing streak for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average also saw gains on the same day.
Resmed Inc Stock (RMD) Moved Up by 3.43% on Aug 19: What Investors Need To Know
Resmed Inc (RMD) saw its stock price increase by 3.43% due to positive investor sentiment surrounding capital allocation milestones, increased dividends, and the divestiture of its MatrixCare business. Technical indicators like MACD and Williams %R suggest a buy signal, while fundamental analysis highlights its solid annual revenue and net profit within the Healthcare Services & Equipment industry. Despite some company-specific risks like ventilator product recalls and market share erosion, investor confidence is bolstered by the company's strategic realignments and resilient core demand for sleep apnea devices.
Oxbow Advisors LLC Invests $5.57 Million in ResMed Inc. $RMD
Oxbow Advisors LLC recently invested $5.57 million in ResMed Inc. by purchasing 28,583 shares. This comes as ResMed exceeded its quarterly earnings expectations with $2.95 EPS and increased its quarterly dividend to $0.66 per share, despite mixed analyst sentiment and an average "Hold" rating. Institutional investors now own 54.98% of the company, and recent insider transactions involved sales by the CEO and a director.
Rothschild Redburn initiates ResMed stock coverage with neutral rating By Investing.com
Rothschild Redburn has initiated coverage of ResMed Inc. (NYSE:RMD) with a Neutral rating and a price target of $230.00. The firm acknowledges ResMed's market leadership in obstructive sleep apnoea (OSA) treatment but struggles to find significant upside to consensus estimates, citing the stock's current full valuation. Despite the neutral rating, ResMed recently reported higher profit and revenue for its fiscal fourth quarter, exceeding Wall Street's earnings expectations.
Rothschild Redburn initiates ResMed stock coverage with neutral rating
Rothschild Redburn has initiated coverage on ResMed Inc. (NYSE:RMD) with a Neutral rating and a price target of $230.00. The firm acknowledges ResMed's market leadership in obstructive sleep apnoea treatment but notes structural barriers and struggles to find meaningful upside to consensus estimates, viewing the current valuation as full. Despite recent strong fiscal fourth-quarter results, analysts are factoring in challenges such as the impact of GLP-1 pharmaceuticals and wearable health devices.
Rothschild Redburn initiates ResMed stock coverage with neutral rating
Rothschild Redburn has initiated coverage on ResMed Inc. (NYSE:RMD) with a Neutral rating and a price target of $230.00, citing the company's market-leading position in obstructive sleep apnea treatment. Despite acknowledging the potential for growth in continuous positive airway pressure (CPAP) therapies, the firm sees structural barriers and believes the current valuation is full, struggling to find meaningful upside to consensus estimates. The analysis also noted ResMed's recent fiscal fourth-quarter results, where it exceeded earnings expectations but slightly missed revenue forecasts.
Rothschild Redburn initiates ResMed stock coverage with neutral rating By Investing.com
Rothschild Redburn has initiated coverage on ResMed Inc. (NYSE:RMD) with a Neutral rating and a price target of $230.00. The firm acknowledges ResMed's market-leading position in treating obstructive sleep apnoea (OSA) but notes structural barriers and sees limited upside to current consensus estimates given the stock's current valuation. Despite the neutral rating, ResMed recently reported strong fiscal fourth-quarter results, exceeding earnings expectations while revenue slightly missed forecasts.
Deutsche Bank AG Takes Position in ResMed Inc. $RMD
Deutsche Bank AG has acquired a new position in ResMed Inc. (NYSE:RMD), purchasing over 1.3 million shares valued at approximately $257 million, representing 0.91% of the company's stock. Other institutional investors have also modified their holdings. Insider transactions show CEO Michael J. Farrell and Director Peter C. Farrell selling shares, while analysts have set various price targets, with the stock currently holding an average "Hold" rating.
Resmed board set to get new lead director
Resmed announced that Carol Burt will become its lead director on November 15, 2026, succeeding Ron Taylor, who is retiring after 21 years of service. Burt has been on Resmed's board since 2013 and chairs the Nominating and Governance Committee. Mick Farrell, Resmed’s chairman and CEO, praised Burt's leadership and Taylor's significant contributions to the company's growth and governance.
RESMED INC CDI COM USD0.004 (10CDI/1SHS) To Go Ex-Dividend On August 19th, 2026 With 0.066 USD Dividend Per Share
RESMED INC CDI COM USD0.004 (10CDI/1SHS) will go ex-dividend on August 19th, 2026. The company is set to pay a dividend of 0.066 USD per share. This information is relevant for investors tracking dividend payouts.
UNIVEST FINANCIAL Corp Acquires Shares of 12,846 ResMed Inc. $RMD
UNIVEST FINANCIAL Corp acquired 12,846 shares of ResMed Inc. (NYSE:RMD) during the second quarter, valued at approximately $2.5 million. ResMed reported strong quarterly earnings, exceeding analyst estimates, and increased its quarterly dividend. Despite insider selling activity totaling around $4.9 million, analysts maintain a consensus "Hold" rating for the stock with a target price of $240.17.
Perigon Wealth Management LLC Invests $4.60 Million in ResMed Inc. $RMD
Perigon Wealth Management LLC has acquired a new position in ResMed Inc. (NYSE:RMD) during the second quarter, purchasing 23,587 shares valued at approximately $4.60 million. Several other institutional investors also bought or sold shares of ResMed, with institutional ownership standing at 54.98%. Analysts have issued mixed ratings, with a consensus "Hold" and an average target price of $240.17, while company insiders have sold shares totaling over $4.8 million in the last three months.
5,358 Shares in ResMed Inc. $RMD Purchased by Flputnam Investment Management Co.
Flputnam Investment Management Co. recently acquired 5,358 shares of ResMed Inc. (NYSE:RMD) valued at approximately $1.04 million during the second quarter. Other institutional investors have also adjusted their stakes in the medical equipment provider, with several increasing their holdings or purchasing new stakes. ResMed also announced a quarterly dividend increase and reported strong quarterly earnings, beating analyst estimates.
ResMed (RMD) Announces Auditor Transition to PwC and Board Leade
ResMed (RMD) has announced the dismissal of KPMG LLP as its independent auditor and the appointment of PricewaterhouseCoopers LLP (PwC) for the fiscal year ending June 30, 2027, following a comprehensive review. Concurrently, director Ronald Taylor will retire from the Board, effective November 18, 2026, and Carol Burt has been appointed as the new lead director, effective November 15, 2026. These changes are not attributed to any disagreements with the company's operations or policies.
ResMed names Carol Burt as lead director, Ron Taylor to retire
ResMed (NYSE:RMD) has announced that Carol Burt will become the new Lead Director on November 15, 2026, succeeding Ron Taylor, who will retire after 21 years on the company's Board of Directors. Taylor joined the board in 2005 and has served as Lead Director since 2013, while Burt, who has been on the board since 2013, currently chairs the Nominating and Governance Committee. The company's CEO, Mick Farrell, praised both Burt's leadership qualities and Taylor's significant contributions to ResMed's governance and growth.
ResMed Inc. stock falls Monday, underperforms market
ResMed Inc. (RMD) shares fell by 1.82% on Monday, closing at $220.37. This performance underperformed the broader market, as both the S&P 500 Index and the Dow Jones Industrial Average also experienced declines. This marks the second consecutive day of losses for ResMed stock.
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
Resmed has announced that Carol Burt will become the new Lead Director on November 15, 2026, succeeding Ron Taylor, who will retire after over 21 years of service. Burt, who currently chairs the Nominating and Governance Committee, will bring extensive governance and healthcare industry experience to the role. The company praised Ron Taylor for his significant contributions to Resmed's growth and strategy over two decades.
Ronald Taylor to Retire from Resmed; Carol Burt Named Lead Director
Ronald Taylor, a director at Resmed (RMD), will retire at the company's 2026 annual meeting. In anticipation of his retirement, the board has appointed Carol Burt as the new lead director, effective November 15, 2026. This change was reported in an SEC 8-K filing on August 17, 2026.
A lead director's 21-year Resmed tenure is set to end in November
Resmed (NYSE: RMD) announced that Carol Burt will become Lead Director effective November 15, 2026, succeeding Ron Taylor, who will retire after over 21 years of service. Burt, who has been a director since 2013 and chairs the Nominating and Governance Committee, is seen as well-prepared for the role due to her extensive experience. The company highlighted Taylor's significant contributions to governance and growth during his tenure.
87,722 Shares in ResMed Inc. $RMD Purchased by Avalon Trust Co
Avalon Trust Co recently acquired a new stake in ResMed Inc. (NYSE:RMD), purchasing 87,722 shares valued at approximately $17.095 million, making it their 28th largest holding. This comes as other institutional investors have also adjusted their positions, and ResMed reported strong quarterly earnings, increased its dividend, and saw some insider selling. Analysts currently rate ResMed with a "Hold" consensus.
41,381 Shares in ResMed Inc. $RMD Acquired by ABN AMRO Bank N.V.
ABN AMRO Bank N.V. has acquired a new stake of 41,381 shares in ResMed Inc. (NYSE:RMD) during the second quarter, valued at approximately $8.07 million. Several other institutional investors also increased their holdings in ResMed, while corporate insiders have recently sold shares. Analysts currently rate ResMed with an average "Hold" rating and a target price of $240.17.
Why You Should Consider Buying ResMed Stock After Its First-Ever Annual Guide
ResMed (RMD) has issued its first annual guidance, targeting $5.75B-$5.85B in FY27 revenue and $12.00-$12.25 non-GAAP EPS, implying a 12-14% core EPS growth when temporary headwinds are excluded. While street analysts are cautious and have trimmed price targets, TIKR's model values ResMed stock at $346 by mid-2031, suggesting a 54% total return. This indicates a disconnect between analyst sentiment and the company's underlying growth story, particularly as temporary drags resolve.
The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call
ResMed (RMD) reported steady revenue growth but a decline in operating margin for its Q2 earnings, largely due to higher R&D and supply chain costs, and a $42 million charge for a field safety action. Analysts focused on gross margin drivers, revenue growth acceleration, acquisition strategy, the Astral field safety process, and the impact of GLP-1s on new patient acquisition. The company emphasized investments in innovation, cost discipline, and strategic tuck-in acquisitions, while noting GLP-1s as a tailwind for CPAP adoption despite initial adherence challenges.
ResMed Inc. stock falls Friday, underperforms market
ResMed Inc. (RMD) stock decreased by 1.01% to $224.46 on Friday, underperforming the broader market as the S&P 500 and Dow Jones Industrial Average also experienced declines. This fall ended a four-day winning streak for the company's shares.
How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds
ResMed Inc. recently announced increased fourth-quarter and full-year sales, a quarterly dividend hike to US$0.66 per share, and the completion of a US$1.40 billion share buyback program. However, these positive developments are overshadowed by a softer outlook due to an FDA Class 1 recall and suspended ventilator sales. The article explores how these factors will influence ResMed's long-term investment appeal, emphasizing the resilience of its sleep-health and digital platforms.
RESMED INC. : RBC RAISES TARGET PRICE TO $244 FROM $234
RBC has increased its target price for ResMed Inc. (RMD) to $244 from $234. This adjustment suggests an updated analyst outlook on the company's stock performance. The news was reported by Reuters on August 7th.
ResMed Inc. Files Annual Form 10-K Report for Fiscal Year Ended June 30, 2026
ResMed Inc. has filed its annual Form 10-K report with the U.S. SEC for the fiscal year ended June 30, 2026, detailing key corporate and financial information. The report confirmed that as of August 10, 2026, ResMed had 144,252,306 shares of Common Stock outstanding and a market capitalization of $34,917,180,979 for non-affiliate held equity as of December 31, 2025. The company is classified as a large accelerated filer listed on the NYSE under RMD and has confirmed compliance with internal control over financial reporting requirements.
RESMED INC FY 2026: Revenue $5.65B, EPS $10.43— 10-K Summary
ResMed Inc. reported strong fiscal year 2026 results, with net revenue climbing to $5.65 billion, a 9.9% increase year-over-year, and diluted EPS reaching $10.43. The company saw growth across all regions, driven by device and mask sales, and improved operational efficiencies led to a higher gross margin. Strategic moves included the acquisition of Noctrix and the divestiture of its MatrixCare business.
How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds
ResMed (RMD) recently reported strong Q4 and full-year results, increasing its quarterly dividend to US$0.66 per share and completing a US$1.40 billion share buyback. However, the company also faces a softer outlook due to an FDA Class 1 recall of ventilators, suspending sales. This creates a mixed investment narrative where the strength of its sleep-health and digital platforms must offset ventilator-related pressures.
Handelsbanken Fonder AB Raises Stock Position in ResMed Inc. $RMD
Handelsbanken Fonder AB significantly increased its stake in ResMed Inc. by 36.6% in the second quarter, now holding 94,895 shares valued at $18.5 million. This move is part of broader institutional investor activity, with a collective 54.98% ownership, despite a mixed analyst sentiment and a consensus "Hold" rating. ResMed reported strong quarterly earnings, beating expectations, increased its dividend, but also saw insider selling activity.
Insulet Corporation (PODD) Stock forecasts
Argus has lowered its target price for Insulet Corporation (PODD) to $159.00 from its previous rating. Insulet, founded in 2000, aims to simplify continuous subcutaneous insulin infusion therapy for diabetes. The stock's current price is $144.68.
Weekly Earnings Wrap: CBA, REA Group, Westpac, Resmed and more
This article provides a weekly wrap-up of earnings season, focusing on major Australian companies like CBA, REA Group, Westpac, ResMed, and Life360. It highlights varying performances, with REA Group benefiting from property market changes and ResMed showing resilient growth despite missed guidance. The report also details analyst views on fair values and outlooks for each company.
ResMed Inc. Stock 12‑Month Price Target Cut to $258.47, Implies 14% Upside
The average 12-month price target for ResMed Inc. (RMD) stock has been revised down slightly to $258.47 from $261.36, as estimated by 22 analysts. This new target suggests a potential 14% upside from the Aug. 12 closing price. The consensus rating among 29 analysts remains a "Buy," with a breakdown of 19 Buys, 9 Holds, and 1 Sell.
Align Technology, Inc. (ALGN) Stock Forecasts
Argus has lowered its target price for Align Technology (ALGN), the leading manufacturer of clear aligners, to $194.00. The company's main product, Invisalign, holds over 90% of the market share. The current stock price for ALGN is $174.01.
ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook
ResMed (RMD) stock appears to be significantly undervalued, with a Discounted Cash Flow (DCF) analysis suggesting a 30.6% discount and its P/E ratio sitting below industry averages. Despite a recent 7% drop due to a softer FY27 outlook and suspended ventilator sales, the underlying cash flows and earnings multiples indicate the stock could be cheap relative to its fundamentals. The key uncertainty lies in how quickly the company can absorb the revenue impact from these headwinds.
ResMed CEO Michael Farrell sells $1.03m in company stock
ResMed CEO Michael Farrell sold $1.03 million worth of company stock on August 7, 2026, by selling 4,991 shares at prices between $202.410 and $204.160. On the same day, he acquired an equal number of shares through options exercise for $730,382 at $146.34 per share, under a pre-arranged trading plan. Following these transactions, Farrell directly holds 466,256 shares and indirectly 2,090 shares.
ResMed Inc. stock rises Tuesday, outperforms market
ResMed Inc. (RMD) shares rose 2.18% to $224.84 on Tuesday, outperforming a generally negative market day where the S&P 500 and Dow Jones Industrial Average both saw declines. This marks the second consecutive day of gains for the stock.
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
Inogen, Inc. (INGN) has lowered its 2026 revenue outlook due to persistent U.S. channel pressure, specifically a decline in direct sales and rentals, despite strong international growth and improved profitability. The company expects 2026 revenues to be between $355 million and $361 million, a reduction from previous estimates. Inogen is focusing on business-to-business efforts and new products like the Voxi stationary oxygen concentrator to adapt to the changing market.
